Synta Pharmaceuticals Presents Results on Ganetespib and Hsp90 Inhibitor Class at the American Association for Cancer Research-European Organization for Research and Treatment of Cancer-National Cancer Institute Molecular Targets and Cancer Therapeutics C

LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that preclinical results presented at the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference show that ganetespib, a potent Hsp90 inhibitor, is highly effective in overcoming mechanisms of resistance in models of multiple oncogene addicted tumors.